Anti-Helicobacter pylori treatment can effectively improve the clinical remission rates of irritable bowel syndrome: a controlled clinical trial meta-analysis-Reference-Cited by-同舟云学术

Anti-Helicobacter pylori treatment can effectively improve the clinical remission rates of irritable bowel syndrome: a controlled clinical trial meta-analysis

Published:2020 Issue: Volume:75 Page:
ISSN:1807-5932
Container-title:Clinics
language:en
Short-container-title:

Author:

Xiong Yan,Liu Lulu,Zhou Xuchun,Wen Youfei,Wang Ruonan

Publisher

Elsevier BV

Subject

General Medicine

Reference42 articles.

1. Analysis of epidemiological investigation of irritable bowel syndrome in China;Li;Chin J Gastroenterol Hepatol,2013

2. Irritable bowel syndrome: the clinical approach;Adriani;Panminerva Med,2018

3. Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV;Drossman;Gastroenterology,2016

4. The role of inflammation in irritable bowel syndrome (IBS);Ng;J Inflamm Res,2018

5. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection;Liu;Helicobacter,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No evidence for a causal link between Helicobacter pylori infection and Irritable bowel syndrome: a Mendelian randomization study;Frontiers in Microbiology;2024-02-07

2. Helicobacterpylori Infection—A Risk Factor for Irritable Bowel Syndrome? An Updated Systematic Review and Meta-Analysis;Medicina;2022-08-02

3. Progress in elucidating the relationship between Helicobacter pylori infection and intestinal diseases;World Journal of Gastroenterology;2021-12-21

4. Erratum for: Anti-Helicobacter pylori treatment can effectively improve the clinical remission rates of irritable bowel syndrome: a controlled clinical trial meta-analysis;Clinics;2021